PBLS Company Profile and Key Details

Parabilis Medicines, Inc. (NASDAQ:PBLS) closed at $36.88 USD, gaining $0.56 (1.54%) from the previous close of $36.32. The stock is currently mid-range between its 52-week high and low $24.51 and $41.49. With a market capitalization of about $4.30 billion, Parabilis Medicines, Inc. is classified as a mid-cap and shows lower-than-market volatility (beta ~0.00). Key stats such as the average daily volume over the past year has been around 547.00 thousand shares, volume is running light vs its 52-week average. Headquartered in Cambridge, MA, Parabilis Medicines, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Mathai Mammen, the company employs approximately 145 people and listed since June 10, 2026. Fog Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company.

Parabilis Medicines, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$15.32. This means the shares are trading below this model’s fair value.

Average 10-day trading volume of 470.47 thousand shares is below the 3-month average of 535.63 thousand, indicating normal recent market interest.

Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $45.00 to $40.00. The high target offers 22.02% upside. The low target suggests 8.46% downside. The mean target is $41.67. This offers 12.99% upside. Parabilis Medicines, Inc. earnings surprise history is a mixed track record. The quarter that ended August 13, 2026, missed forecasts by 1306.06%.

Parabilis Medicines, Inc. has 121.95 million shares outstanding. The public float is 82.07 million shares, elevated short interest at 4.24% of float. This equals 5.12 million shares. The short ratio is 11.48 days. Institutional investors hold 59.56% of the float. Insiders own 3.78%. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Our AI price prediction model suggests that Parabilis Medicines, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 1.03%, with price expected at $37.26 by September 25, 2026, within a range of $36.37 to $38.24 3-Month Outlook: Projected rise of 57.16%, reaching $57.96 by December 09, 2026, with a range of $57.69 to $58.21. 1-Year Outlook: Projected gain of 81.94%, with price at $67.10 by September 10, 2027, within a range of $66.80 to $67.35.

Valuation shows Parabilis Medicines, Inc. trading at a premium to the broader market with a P/E of -1.0. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $41.67, suggesting 12.99% upside. Our AI forecast model points to short-term strength (1.03% over two weeks), a medium-term rise (57.16% over three months), and a longer-term gain (81.94% over one year), with expected trading ranges indicating moderate volatility.

Parabilis Medicines, Inc. trades at a P/E ratio of -1.0, slightly below the S&P 500 average, with a price-to-sales ratio of 29093.89 and a price-to-book ratio of 1.02 suggesting the stock is closer to book value. The P/FCF stands at -80.02, also below market averages.